相关临床试验
6
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
33.3%
招募中
3
50.0%
撤回
1
16.7%
暂无批准数据
- Kurma Partners closed its Biofund IV at €215 million, a substantial specialist fund focused on early-stage European biotech company creation despite falling short of its original €250 million target. - The fund plans 16 to 20 investments with 80% of capital directed toward companies developing new therapeutic solutions for diseases with high unmet need. - Biofund IV has already deployed capital into multiple companies including Memo Therapeutics, Avidicure, EvlaBio, Nuevocor, Elkedonia, and Laigo Bio across diverse therapeutic areas. - Kurma's track record includes three major Biofund III exits: Amolyt Pharma acquired by AstraZeneca for up to $1.05 billion, Corlieve Therapeutics acquired by uniQure, and Emergence Therapeutics acquired by Eli Lilly.
- European venture capital firm Sofinnova Partners has raised €1.2 billion ($1.3 billion) in fresh funds to invest in life sciences and healthcare companies, with plans to support 50-60 new ventures. - Since 2022, Sofinnova has backed 21 biotech companies across various therapeutic modalities, including gene therapy company Chroma Medicine and AstraZeneca-acquired firms CinCor Pharma and Amolyt Pharma. - The fundraise comes amid a shifting venture capital landscape, where total biotech funds have decreased from 137 in 2021 to 38 in 2024, with investors increasingly prioritizing companies with validated clinical data and clear commercialization pathways.
